Solventum (NYSE:SOLV) Coverage Initiated by Analysts at Rothschild & Co Redburn

Stock analysts at Rothschild & Co Redburn started coverage on shares of Solventum (NYSE:SOLV) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set a “sell” rating and a $60.00 price target on the stock. Rothschild & Co Redburn’s target price suggests a potential downside of 8.73% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. BTIG Research reissued a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Finally, Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $90.64.

Solventum Trading Down 0.1%

Shares of NYSE SOLV opened at $65.74 on Tuesday. Solventum has a twelve month low of $60.70 and a twelve month high of $88.20. The firm has a market cap of $11.41 billion, a PE ratio of 7.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. The business has a fifty day simple moving average of $74.32 and a two-hundred day simple moving average of $75.78. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter in the prior year, the company earned $1.41 EPS. The business’s revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Insider Transactions at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of Solventum stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Solventum

A number of large investors have recently modified their holdings of SOLV. Hsbc Holdings PLC increased its holdings in shares of Solventum by 2.3% during the fourth quarter. Hsbc Holdings PLC now owns 227,139 shares of the company’s stock valued at $18,021,000 after acquiring an additional 5,015 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in Solventum by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 6,450 shares of the company’s stock worth $511,000 after purchasing an additional 864 shares in the last quarter. Corient Private Wealth LLC grew its position in Solventum by 18.5% during the 4th quarter. Corient Private Wealth LLC now owns 49,092 shares of the company’s stock worth $3,859,000 after purchasing an additional 7,653 shares during the last quarter. Bayban acquired a new position in Solventum during the 4th quarter valued at approximately $134,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Solventum by 80.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company’s stock worth $34,000 after buying an additional 191 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.